REHOVOT, Israel and BRIDGEWATER, N.J., March 10, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will release fourth quarter and fiscal year 2014 financial results and host a conference call and webcast on Wednesday, March 18, 2015.

Conference Call & Webcast
Wednesday, March 18, 2015 @ 8:00am Eastern/5:00am Pacific
Domestic:  888-572-7034
International:  719-325-2376
Conference ID:  2501517
Replays available until April 1, 2015
Domestic:  877-870-5176
International:  858-384-5517
Passcode:  2501517

About Foamix Pharmaceuticals Ltd.

Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix Pharmaceuticals' lead product candidate FMX101 for moderate-to-severe acne is a novel topical foam formulation of the antibiotic minocycline. Foamix Pharmaceuticals also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.  

Cautionary Note Regarding Forward-Looking Statements

This press release may contain "forward-looking statements" relating to future events. Forward-looking statements are based on Foamix Pharmaceuticals' current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. Any forward-looking statements that may be made herein speak only as of the date of this release and Foamix Pharmaceuticals undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
CONTACT: Ilan Hadar, CFO         Foamix Pharmaceuticals Ltd.         +972-8-9316233                  U.S. Investor Relations         Michael Rice         LifeSci Advisors, LLC         646-597-6979

Foamix, Ltd. logo